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Background: The proteomic analysis of body fluids is a growing technology for the identification of protein
biomarkers of disease. Given that Papanicolaou tests (Pap tests) are routinely performed on over 30 million women
annually in the U.S. to screen for cervical cancer, we examined the residual Pap test fluid as a source of protein for
analysis by mass spectrometry (MS). In the liquid-based Pap test, cervical cells are collected from the ectocervix and
placed into an alcohol-based fixative prior to staining and pathologic examination. We hypothesized that proteins
shed by cells of the female genital tract can be detected in the Pap test fixative by MS-based proteomic techniques.
We examined the feasibility of using residual fluid from discarded Pap tests with cytologically “normal” results to
optimize sample preparation for MS analysis. The protein composition of the cell-free Pap test fluid was determined
by silver staining of sodium dodecyl sulfate -polyacrylamide gels, and the abundance of serum proteins was
examined by Western immunoblot using an antibody against human serum albumin. Both pooled and individual
samples were trypsin digested and analyzed by two-dimensional MS/MS. Proteins were identified by searching
against the Human Uniprot database, and characterized for localization, function and relative abundance.
Results: The average volume of the residual Pap test fluid was 1.5 ml and the average protein concentration was
0.14 mg/ml. By Western immunoblot we showed that the amount of albumin in each sample was significantly
reduced compared to normal serum. By MS/MS, we identified 714 unique proteins in pooled Pap test samples and
an average of 431 proteins in individual samples. About 40% of the proteins identified were extracellular or
localized to the plasma membrane. Almost 20% of the proteins identified were involved in immunity and defense,
characteristic of the healthy cervical-vaginal proteome. By merging the protein sets from the individual and pooled
Pap test samples, we created a “Normal Pap test Core Proteome” consisting of 153 proteins.
Conclusions: Residual Pap test fluid contains a sufficient amount of protein for analysis by MS and represents a
valuable biospecimen source for the identification of protein biomarkers for gynecological diseases.
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Screening for cervical cancer by Papanicolaou tests
(Pap tests) has been routinely performed for over 50 years
[1]. The liquid-based Pap test consists of collecting cervical
cells from the ectocervix and placing them into a vial con-
taining a fluid transport medium to preserve the cells [2,3].* Correspondence: skubi002@umn.edu
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unless otherwise stated.Two FDA approved liquid-based Pap tests are widely
used for the screening and detection of cervical cancer,
pre-cancerous lesions, and atypical cells [4]. One Pap
test, which we used in this study, is the SurePathTM Pap
test [Becton-Dickinson (BD Diagnostics, Burlington, NC)]
which has an alcohol-based fixative consisting of 21.7%
ethanol, 1.2% methanol, 1.1% isopropanol, and formal-
dehyde [5]. The second Pap test, the ThinPrep Pap test
(Hologic, Inc., Bedford, MA) contains 30-60% methanol
as the fixative [6]. In each case, fixative is removed fromLtd. This is an Open Access article distributed under the terms of the Creative
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the cells are stained on a slide, and then examined by a
pathologist to identify the presence of premalignant
and malignant cells. The liquid fixative solution in
which the cells are collected for Pap tests is routinely
discarded after examination of the cells. Over 30 million
Pap tests are analyzed annually by cytopathologists
[4,7-9]; making this an abundant source of samples for ex-
perimentation and for the potential detection of a variety
of gynecological diseases in the future. To our knowledge,
no one has analyzed the residual Pap test fluid by the latest
mass spectrometry (MS)-based proteomic techniques to
identify proteins or potential biomarkers of disease.
Several groups have performed mass spectrometry-
based proteomic analysis of cervical-vaginal fluid obtained
using swabs, gauze, or Dacron-tipped plastic applicators
(reviewed in [10]). Cervical-vaginal fluid is a complex bio-
logical fluid that protects and lubricates the endometrial,
cervical and vaginal lining. This fluid contains proteins
predominantly synthesized by the endocervix and vaginal
cells, but it has been shown to also contain proteins from
amniotic fluid leakage during pregnancy, from endomet-
rial and tubal secretions, and the peritoneal fluid [11-15].
Studies have attempted to define the proteome of
healthy women as well as identify potential markers for
preterm birth, pregnancy, and intra-amnionic infection
[10,11,13-21]. However, to date, the use of residual Pap
test fluid as a source for proteomics and biomarker
discovery has not been reported.
The primary objective of this study was to determine
whether residual Pap test fixative is a suitable source of
protein for mass spectrometry-based proteomic techniques.
We have quantified the concentration of protein present in
the residual SurePathTM fixative of Pap tests taken from
over 100 women with normal cytology. We developed a
protocol for processing the residual Pap test fluid so that
peptides can be analyzed by MS/MS and proteins identified
from the Human Uniprot database. Finally, we found ex-
tensive overlap between the proteins that we define as our
“Normal Pap test Core Proteome” and lists of cervical-
vaginal fluid proteins identified by others using different
sampling methods [10,11,13-15,17-22].
Results
Cell-free residual Pap test fluid contains protein
To determine whether the cell-free fluid remaining after
the examination of cervical cells from the SurePathTM
liquid based Pap test preparation contained sufficient
protein for mass spectrometry analysis, we measured
the volume and protein content of over 100 residual
SurePathTM samples. On average, these samples contained
1.5 ml of SurePathTM fixative. The protein concentration in
72 of the samples was determined using the bicinchoninic
acid (BCA) protein assay (Pierce Protein Research Products,Rockford, IL) on duplicate samples and ranged from un-
detectable to more than 0.7 mg/ml; with an average protein
concentration of 0.14 mg/ml (Figure 1A). Sixteen of these
72 Pap test fixative samples were randomly selected to be
examined by sodium dodecyl sulfate (SDS)-polyacrylamide
gel electrophoresis (PAGE). We found many protein
bands visible by silver stain, indicating the presence of
both high and low abundance proteins in residual Pap
test fluid (Figure 1B). Overall, the protein patterns ap-
peared relatively similar in number, size, and intensity
among the individual samples. Several major protein
bands of 50–250 kD were detected in almost all of the
samples, as well as proteins of ~25 kD and 10–15 kD.
To determine whether the variation in protein concen-
tration of the residual Pap test fluid was due to contamin-
ation of the samples with blood proteins, we separated the
proteins from the residual Pap test fluid of five individuals
by size on SDS-PAGE (Figure 1C) and then performed
Western immunoblot analysis of the protein using an
antibody to human serum albumin (Figure 1D). Compari-
son of an equal amount of serum (lane 6; S) to the protein
in the residual Pap test fluid (lanes 1–5) showed the
variable presence of albumin in each of the residual
Pap test samples, however at a substantially lower level
than was found in serum (lane 6). The results of the
Western immunoblot analysis also demonstrated that
the protein concentration of the residual Pap test fluid
did not directly correlate with the level of serum albu-
min present. For example, the sample with the highest
protein concentration of 0.5 mg/ml (Figure 1C and D,
lane 2, large arrow) did not contain more serum albu-
min than the other samples. Similarly, the sample in
which the least amount of serum albumin was detected
(Figure 1C and D, lane 4, small arrow) had the second
highest protein concentration of 0.4 mg/ml.
Mass spectrometry of pooled Pap test samples
In order to get an overview of the proteins present in the
SurePathTM fluid, we pooled residual Pap test fluid from
40 women with normal cervical cytology for analysis by
2D tandem mass spectrometry. These 40 samples were se-
lected from the 56 samples that remained from the ori-
ginal 72 samples (Figure 1A), after 16 samples were used
for SDS-PAGE analysis (Figure 1B). The selection of these
40 samples was based solely on the fact that they con-
tained >50 ug of protein. A total of 714 unique proteins
were identified when the pooled samples were run in two
separate experiments (see Additional file 1). Only proteins
from UniProtKB/Swiss-Prot (reviewed) are reported in
Additional file 1. The cellular localization of the 714
proteins was determined using Gene Ontology (GO) clas-
sifications (Figure 2A) [23]. Over 40% of the proteins
identified in the pooled Pap test samples were extra-
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Figure 1 Protein content of residual Pap test fluid. (A) The protein concentration of residual Pap test fluid from 72 randomly selected
SurePathTM samples was measured using the BCA protein assay in duplicate. Error bars show standard deviation. (B) The protein composition of
the cell-free Pap test fluid from 16 individuals randomly selected from the samples in (A) was visualized by silver staining of SDS-PAGE gels. Five
micrograms of protein was loaded per lane. MW, molecular weight standards. (C) Five micrograms of protein from serum (lane 6; S) or 5 different
individuals’ SurePathTM samples (lanes 1–5) with varying protein concentrations (0.1–0.5 mg/ml) were visualized by silver stained SDS-PAGE. (D) In
a parallel experiment, the SDS-PAGE gels was transferred to a PVDF membrane and probed by Western immunoblot with a polyclonal antibody
recognizing human serum albumin. In (C) and (D), the protein concentration of the individual’s Pap test sample is listed above each lane. The
large arrow indicates the individual’s Pap test sample with the highest protein concentration (lane 2; 0.5 mg/ml), and the small arrow indicates
the individual’s Pap test sample with the lowest serum albumin content as detected by Western immunoblotting (lane 4).
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suggesting the occurrence of cell lysis in situ. The pro-
teins identified in the pooled Pap test samples were also
classified according to several general functional terms by
the PANTHER classification system (Figure 2B) [24] and
grouped into over a dozen categories. The major func-
tional groups contained proteins involved in immunity
and defense (19%), protein metabolism and modification
(15%), the cytoskeleton (10%), and other cellular processes
such as cell signaling (10%) and cell adhesion (5%). Minor
groups of proteins were involved in transport (4%), cell
cycle (3%), and reproduction (2%).Sources of variability in mass spectrometry analysis
In LC/MS proteomic studies, several sources of variability
exist, including biological, technical, and experimental
[25,26]. In order to address the issue of technical variability
which occurs during sample preparation (including trypsin
digestion and solid phase extraction clean up), we randomly
selected a Pap test sample from a healthy individual and
precipitated the protein with acetone. The protein was then
divided into two identical aliquots. These two samples were
then digested by the filter aided sample preparation FASP
technique in parallel and then these replicates were ana-




















































Pooled Pap test Proteins
A
B
Figure 2 Classification of proteins in the pooled Pap test samples by cellular localization and function. The proteins in the two pooled
samples were combined into one group of 714 proteins. These proteins were then classified by cellular localization and biological function using
PANTHER database (version 8.1) and Ingenuity IPA (version 2013, 17199142) and the UniProtKB Protein Knowledge database. (A) Most of the
proteins (608/714) were classified according to cellular localization. The remaining 106 proteins were unclassified. (B) Most of the proteins
(685/714) were classified according to biological function. The remaining 29 proteins were unclassified.
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to have a variance of 1.23×10−3 with a CV of 19.23%.
We then performed independent injections of one
aliquot in three different MS runs; the short-term run-
to-run instrumental variance was estimated to be 5.69×10−4.
These results are comparable to values obtained in the
literature [25,26].Mass spectrometry of individual Pap test samples
Five residual Pap test samples were randomly selected from
a second cohort of 20 individuals with normal cytology
and were prepared for mass spectrometry using the FASP
technique (see Methods). On average, 431 proteins were
identified in the individual samples (ranging from 317 to
539 proteins) (Table 1 and Additional file 2). Only proteins
Table 1 Proteins identified in individual residual Pap
test samples
Individual Pap test samples
NP94 NP134 NP137 NP929 NP933
Total number of proteins
identified by MS/MS in
this individual’s Pap test(a)
321 317 539 500 479
Number of this individual’s
proteins also identified in
the pooled samples(b)
280 257 293 311 286
Number of this individual’s
proteins also identified in
the “Normal Pap test
Core Proteome” (c)
131 124 137 152 152
Proteins were identified from the MS/MS data for each of the 5 individual Pap
test samples from women with normal cytology.
(a)The total number of proteins identified in each individual Pap test was
counted and the proteins listed in Additional file 2. False positive rates
were < 1.0% for all experiments.
(b)The lists of proteins that were identified for each individual were compared
to the list of 714 proteins identified in the pooled Pap test samples (listed in
Additional file 1).
(c)The lists of proteins that were identified for each individual were compared
to the list of 153 proteins identified in our newly defined “Normal Pap test
Core Proteome” (listed in Table 2).
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Additional file 2. Approximately 70% (60-85%) of the pro-
teins identified in the individual samples were also found in
the pooled samples (Table 1). The lists of proteins that were
identified in the Pap test fluid from each of five individuals
(Additional file 2) were then analyzed for their frequency of
occurrence. The 153 proteins that were present in 4 of the
5 individuals are hereafter designated the, “Normal Pap test
Core Proteome” and are listed in Table 2 with their Protein
name, Gene name, and Swiss-Prot accession number.
Classification of all 153 proteins in the “Normal Pap
test Core Proteome” based on cellular localization
(Figure 3A) shows that most of the proteins were de-
rived from the cytoplasm (59%), and over one third of
the proteins were extracellular (29%) or in the plasma
membrane (9%), which is in agreement with the pooled
sample cellular localization categories (Figure 2A).
Functional classification of the 153 proteins in the
“Normal Pap test Core Proteome” (Figure 3B) is also
similar to the pooled samples and shows a great diver-
sity of biological roles, in which immunity and defense
(20%), cytoskeletal proteins (15%), and protein metab-
olism and modification (12%) are the largest categories
(Figure 2B). One difference between the functional cat-
egories of proteins present in the Pooled Pap test and
the “Normal Pap test Core Proteome” is the percentage
of proteins involved in blood circulation and coagula-
tion that were identified. In the “Normal Pap test Core
Proteome”, 18/153 (12%) were categorized as function-
ing in blood circulation and coagulation. In contrast,
in the Pooled Pap test samples, only 5% (36 of 685) of
the proteins were in this category.Overlap of “Normal Pap Test Core Proteome” with other
CVF proteomic studies
In a comprehensive proteomic analysis of cervical-
vaginal fluid (CVF), Zegels et al. [13] determined a set of
136 “CVF Core Proteins” which were present in at least
three of the four most comprehensive analyses of the
CVF proteome [11,13,15,20]. We compared the lists of
proteins that we had identified in the residual Pap test
fluid of the 5 individuals (Additional file 2) to the list of
“CVF Core Proteins”, and found 132 of the 136 “CVF
Core Proteins” were present in at least one of the individual
Pap test samples. Furthermore, about half (64) of the 153
proteins listed in our “Normal Pap test Core Proteome”
were also present in the “CVF Core Proteome” (Table 2,
column 5). An additional 61 of the proteins in our “Normal
Pap test Core Proteome” were also found in at least one
of ten analyses of CVF proteins enumerated in a recent
review [10] (Table 2, last column). These data demon-
strate that the use of residual Pap test fluid for the iden-
tification of CVF proteins is similar to other sampling
and detection methodologies.
Estimation of protein abundance
We estimated the relative abundance of the proteins
identified in the individual and pooled Pap test samples by
calculating a normalized spectral abundance factor (NSAF)
for each protein (Additional files 1 and 2, last column) that
takes into account both the spectral counts for each protein
as well as the protein size [13,27,28]. Ten of the “Normal
Pap test Core” proteins were among the thirty most
abundant proteins in at least five experiments. These
proteins include neutrophil gelatinase-associated lipocalin,
serotransferrin, lactotransferrin, S100A8 and S100A9, which
all play a role in immune response. Albumin, hemoglobin
alpha, and hemoglobin beta were also among the ten pro-
teins found in at least five experiments.
Discussion
This study represents the first publication in which the
cell-free residual Pap test fluid has been examined as a
source for proteomic profiling of CVF in women with
normal cervical cytology. Using pooled samples, we
identified more than 700 unique proteins; while in in-
dividual Pap test samples more than 300 proteins were
identified. By merging proteins identified in the pooled
samples with proteins identified in 4 of 5 individual
Pap tests analyzed by MS, we determined a “Normal
Pap test Core Proteome” of 153 proteins that is similar
in composition to that of other proteomic analyses of
CVF [10,11,13-15,17,18,20-22].
Previous characterization of the CVF proteome has
relied on sampling methods such as Dacron tipped
swabs [15,17,19,20], sponges or gauze [11,16], or direct
collection of CVF [29,30] or cervical washings [13,14].
Table 2 “Normal Pap test Core Proteome,” defined as the 153 proteins that were identified by MS/MS in the residual
Pap test fluid from 4 out of 5 women with normal cytology
Identified proteins Gene
name
Accession number Present in CVF
Core Proteome*
Present in at least one other
CVF Proteome study**
1 14-3-3 protein epsilon YWHAE [Swiss-Prot: P62258] X
2 14-3-3 protein zeta/delta YWHAZ [Swiss-Prot: P63104] √
3 40S ribosomal protein S16 RPS16 [Swiss-Prot: P62249] X
4 78 kDa glucose-regulated protein HSPA5 [Swiss-Prot: P11021] √
5 Acid ceramidase ASAH1 [Swiss-Prot: Q13510]
6 Actin, cytoplasmic 1 ACTB [Swiss-Prot: P60709] √
7 Acylamino-acid-releasing enzyme APEH [Swiss-Prot: P13798]
8 Adenylate kinase 2, mitochondrial AK2 [Swiss-Prot: P54819]
9 Afamin AFM [Swiss-Prot: P43652] X
10 Alpha-1-antitrypsin SERPINA1 [Swiss-Prot: P01009] √
11 Alpha-1B-glycoprotein A1BG [Swiss-Prot: P04217] X
12 Alpha-2-HS-glycoprotein AHSG [Swiss-Prot: P02765] √
13 Alpha-2-macroglobulin A2M [Swiss-Prot: P01023] X
14 Alpha-actinin-1 ACTN1 [Swiss-Prot: P12814] X
15 Alpha-actinin-4 ACTN4 [Swiss-Prot: O43707] √
16 Alpha-enolase ENO1 [Swiss-Prot: P06733] √
17 Annexin A1 ANXA1 [Swiss-Prot: P04083] √
18 Annexin A11 ANXA11 [Swiss-Prot: P50995] X
19 Annexin A2 ANXA2 [Swiss-Prot: P07355] √
20 Annexin A3 ANXA3 [Swiss-Prot: P12429] √
21 Annexin A5 ANXA5 [Swiss-Prot: P08758] X
22 Apolipoprotein D APOD [Swiss-Prot: P05090] X
23 Aspartate aminotransferase, cytoplasmic GOT1 [Swiss-Prot: P17174] X
24 Aspartate aminotransferase, mitochondrial GOT2 [Swiss-Prot: P00505]
25 Beta-2-glycoprotein 1 APOH [Swiss-Prot: P02749] √
26 Brain acid soluble protein 1 BASP1 [Swiss-Prot: P80723] X
27 Cadherin-1 CDH1 [Swiss-Prot: P12830] X
28 Calmodulin-like protein 3 CALML3 [Swiss-Prot: P27482] √
29 Calpain-1 catalytic subunit CAPN1 [Swiss-Prot: P07384] X
30 Catalase CAT [Swiss-Prot: P04040] √
31 Cathepsin B CTSB [Swiss-Prot: P07858] √
32 Cathepsin D CTSD [Swiss-Prot: P07339] X
33 Cathepsin G CTSG [Swiss-Prot: P08311] √
34 CD44 antigen CD44 [Swiss-Prot: P16070]
35 Ceruloplasmin CP [Swiss-Prot: P00450] √
36 Chitotriosidase-1 CHIT1 [Swiss-Prot: Q13231] X
37 Complement C3 C3 [Swiss-Prot: P01024] √
38 Complement C4-A C4A [Swiss-Prot: P0C0L4] X
39 Complement component C8 gamma chain C8G [Swiss-Prot: P07360]
40 Complement decay-accelerating factor CD55 [Swiss-Prot: P08174] X
41 Complement factor H CFH [Swiss-Prot: P08603] √
42 Cystatin-B CSTB [Swiss-Prot: P04080] √
43 Cytochrome c CYCS [Swiss-Prot: P99999] X
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Table 2 “Normal Pap test Core Proteome,” defined as the 153 proteins that were identified by MS/MS in the residual
Pap test fluid from 4 out of 5 women with normal cytology (Continued)
44 Dipeptidyl peptidase 4 DPP4 [Swiss-Prot: P27487] X
45 Elongation factor 1-alpha 1 EEF1A1 [Swiss-Prot: P68104] √
46 Elongation factor 1-gamma EEF1G [Swiss-Prot: P26641] X
47 Epididymal secretory protein E1 NPC2 [Swiss-Prot: P61916] X
48 Erythrocyte band 7 integral membrane protein STOM [Swiss-Prot: P27105] X
49 Ezrin EZR [Swiss-Prot: P15311] X
50 Ferritin heavy chain FTH1 [Swiss-Prot: P02794]
51 Ferritin light chain FTL [Swiss-Prot: P02792] X
52 Fibrinogen beta chain FGB [Swiss-Prot: P02675] √
53 Fibrinogen gamma chain FGG [Swiss-Prot: P02679] √
54 Fibronectin FN1 [Swiss-Prot: P02751] X
55 Fructose-bisphosphate aldolase A ALDOA [Swiss-Prot: P04075] √
56 Galectin-3-binding protein LGALS3BP [Swiss-Prot: Q08380] X
57 Gamma-glutamylcyclotransferase GGCT [Swiss-Prot: O75223] √
58 Gelsolin GSN [Swiss-Prot: P06396] X
59 Glutamine synthetase GLUL [Swiss-Prot: P15104] X
60 Glutathione reductase, mitochondrial GSR [Swiss-Prot: P00390] X
61 Glutathione synthetase GSS [Swiss-Prot: P48637]
62 Glyceraldehyde-3-phosphate dehydrogenase GAPDH [Swiss-Prot: P04406] √
63 Haptoglobin HP [Swiss-Prot: P00738] √
64 Heat shock cognate 71 kDa protein HSPA8 [Swiss-Prot: P11142] √
65 Heat shock protein beta-1 HSPB1 [Swiss-Prot: P04792] √
66 Heme-binding protein 2 HEBP2 [Swiss-Prot: Q9Y5Z4]
67 Hemoglobin subunit alpha HBA1 [Swiss-Prot: P69905] √
68 Hemoglobin subunit beta HBB [Swiss-Prot: P68871] √
69 Hemopexin HPX [Swiss-Prot: P02790] √
70 Histidine-rich glycoprotein HRG [Swiss-Prot: P04196] X
71 Histone H4 HIST1H4A [Swiss-Prot: P62805] √
72 Ig alpha-1 chain C region IGHA1 [Swiss-Prot: P01876] √
73 Ig gamma-1 chain C region IGHG1 [Swiss-Prot: P01857] √
74 Ig gamma-3 chain C region IGHG3 [Swiss-Prot: P01860] X
75 Ig lambda-2 chain C regions IGLC2 [Swiss-Prot: P0CG05]
76 Ig lambda-7 chain C region IGLC7 [Swiss-Prot: A0M8Q6]
77 Ig mu chain C region IGHM [Swiss-Prot: P01871] √
78 IgGFc-binding protein FCGBP [Swiss-Prot: Q9Y6R7]
79 Immunoglobulin J chain IGJ [Swiss-Prot: P01591] √
80 Involucrin IVL [Swiss-Prot: P07476] √
81 Keratin, type I cytoskeletal 10 KRT10 [Swiss-Prot: P13645]
82 Keratin, type I cytoskeletal 13 KRT13 [Swiss-Prot: P13646]
83 Keratin, type I cytoskeletal 14 KRT14 [Swiss-Prot: P02533]
84 Keratin, type I cytoskeletal 19 KRT19 [Swiss-Prot: P08727]
85 Keratin, type II cytoskeletal 1 KRT1 [Swiss-Prot: P04264]
86 Keratin, type II cytoskeletal 2 KRT2 [Swiss-Prot : P35908]
87 Keratin, type II cytoskeletal 4 KRT4 [Swiss-Prot: P19013]
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Table 2 “Normal Pap test Core Proteome,” defined as the 153 proteins that were identified by MS/MS in the residual
Pap test fluid from 4 out of 5 women with normal cytology (Continued)
88 Keratin, type II cytoskeletal 5 KRT5 [Swiss-Prot: P13647]
89 Keratin, type II cytoskeletal 6A KRT6A [Swiss-Prot: P02538]
90 Kininogen-1 KNG1 [Swiss-Prot: P01042] X
91 Lactotransferrin LTF [Swiss-Prot: P02788] √
92 Lamin-A/C LMNA [Swiss-Prot: P02545] √
93 Leucine-rich alpha-2-glycoprotein LRG1 [Swiss-Prot: P02750] X
94 Leukocyte elastase inhibitor SERPINB1 [Swiss-Prot: P30740] √
95 Long palate, lung and nasal epithelium
carcinoma-associated protein 1
LPLUNC1 [Swiss-Prot: Q8TDL5] X
96 Ly6/PLAUR domain-containing protein 3 LYPD3 [Swiss-Prot: O95274] X
97 Macrophage-capping protein CAPG [Swiss-Prot: P40121] X
98 Moesin MSN [Swiss-Prot: P26038] √
99 Mucin-16 MUC16 [Swiss-Prot: Q8WXI7] X
100 Mucin-5 AC MUC5AC [Swiss-Prot: P98088] X
101 Mucin-5B MUC5B [Swiss-Prot: Q9HC84] √
102 Myeloperoxidase MPO [Swiss-Prot: P05164] √
103 Myosin-9 MYH9 [Swiss-Prot: P35579] √
104 Neuroblast differentiation-associated
protein AHNAK
AHNAK [Swiss-Prot: Q09666] √
105 Neutrophil gelatinase-associated lipocalin LCN2 [Swiss-Prot: P80188] √
106 NSFL1 cofactor p47 NSFL1C [Swiss-Prot: Q9UNZ2] X
107 Peptidyl-prolyl cis-trans isomerase B PPIB [Swiss-Prot: P23284] X
108 Periplakin PPL [Swiss-Prot: O60437] √
109 Peroxiredoxin-1 PRDX1 [Swiss-Prot: Q06830] √
110 Peroxiredoxin-2 PRDX2 [Swiss-Prot: P32119] X
111 Peroxiredoxin-5, mitochondrial PRDX5 [Swiss-Prot: P30044] X
112 Peroxiredoxin-6 PRDX6 [Swiss-Prot: P30041] X
113 Phosphoglycerate mutase 1 PGAM1 [Swiss-Prot: P18669] √
114 Plasma protease C1 inhibitor SERPING1 [Swiss-Prot: P05155] X
115 Plasminogen PLG [Swiss-Prot: P00747] X
116 Plastin-2 LCP1 [Swiss-Prot: P13796] √
117 Polymeric immunoglobulin receptor PIGR [Swiss-Prot: P01833] √
118 Profilin-1 PFN1 [Swiss-Prot: P07737] √
119 Proteasome subunit alpha type-1 PSMA1 [Swiss-Prot: P25786]
120 Proteasome subunit alpha type-3 PSMA3 [Swiss-Prot: P25788]
121 Proteasome subunit alpha type-4 PSMA4 [Swiss-Prot: P25789] X
122 Proteasome subunit alpha type-5 PSMA5 [Swiss-Prot: P28066] X
123 Proteasome subunit alpha type-6 PSMA6 [Swiss-Prot: P60900] X
124 Proteasome subunit beta type-1 PSMB1 [Swiss-Prot: P20618]
125 Proteasome subunit beta type-4 PSMB4 [Swiss-Prot: P28070]
126 Proteasome subunit beta type-6 PSMB6 [Swiss-Prot: P28072]
127 Proteasome subunit beta type-8 PSMB8 [Swiss-Prot: P28062]
128 Protein disulfide-isomerase P4HB [Swiss-Prot: P07237] √
129 Protein disulfide-isomerase A3 PDIA3 [Swiss-Prot: P30101] X
130 Protein disulfide-isomerase A4 PDIA4 [Swiss-Prot: P13667] X
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Table 2 “Normal Pap test Core Proteome,” defined as the 153 proteins that were identified by MS/MS in the residual
Pap test fluid from 4 out of 5 women with normal cytology (Continued)
131 Protein disulfide-isomerase A6 PDIA6 [Swiss-Prot: Q15084] X
132 Protein DJ-1 PARK7 [Swiss-Prot: Q99497]
133 Protein S100-A8 S100A8 [Swiss-Prot: P05109] √
134 Protein S100-A9 S100A9 [Swiss-Prot: P06702] √
135 Pyruvate kinase isozymes M1/M2 PKM2 [Swiss-Prot: P14618] √
136 Ras GTPase-activating-like protein IQGAP1 IQGAP1 [Swiss-Prot: P46940] X
137 Selenium-binding protein 1 SELENBP1 [Swiss-Prot: Q13228]
138 Serotransferrin TF [Swiss-Prot: P02787] √
139 Serpin B6 SERPINB6 [Swiss-Prot: P35237] X
140 Serum albumin ALB [Swiss-Prot: P02768] √
141 Sulfhydryl oxidase 1 QSOX1 [Swiss-Prot: O00391] X
142 Superoxide dismutase [Cu-Zn] SOD1 [Swiss-Prot: P00441] √
143 Synaptic vesicle membrane protein VAT-1 VAT1 [Swiss-Prot: Q99536] X
144 Thioredoxin TXN [Swiss-Prot: P10599] √
145 Transaldolase TALDO1 [Swiss-Prot: P37837] √
146 Transitional endoplasmic reticulum ATPase VCP [Swiss-Prot: P55072] X
147 Transketolase TKT [Swiss-Prot: P29401] X
148 Triosephosphate isomerase TPI1 [Swiss-Prot: P60174] √
149 Vimentin VIM [Swiss-Prot: P08670] √
150 Vinculin VCL [Swiss-Prot: P18206] √
151 Vitamin D-binding protein GC [Swiss-Prot: P02774] √
152 Vitronectin VTN [Swiss-Prot: P04004] X
153 Zinc-alpha-2-glycoprotein AZGP1 [Swiss-Prot: P25311] X
*Present in the 136 Cervical-Vaginal Fluid Core proteins defined by Zegels et al. [13].
**Proteins that were not identified in the 136 Cervical-Vaginal Fluid Core proteins defined by Zegels et al. [13] but were present in at least one of ten previous
studies reviewed by Zegels et al. [10]
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washings collected during colposcopy, were routine clinical
samples utilized for proteomics. In addition, our MS/MS
proteomic technique using the individual residual Pap test
samples still yielded as many or more protein identifica-
tions than previously reported proteomic analyses of CVF,
which at most found 685 proteins [10,13]. The use of the
FASP protocol for trypsin digestion combined with sensi-
tive instrumentation for the mass spectrometry analysis
made the analysis of individual specimens possible.
We used Genome Ontology databases to classify the
proteins identified in residual Pap test fluid by cellular
localization and biological processes [23,24]. In both the
pooled and individual samples, approximately 40% of the
proteins identified were localized to the plasma mem-
brane or extracellular compartments. This is similar to
other studies of CVF which found approximately 30%
of the proteins identified were extracellular or mem-
branous in origin [10,11,13]. Similarly, we also identi-
fied many proteins involved in immunity and defense,
proteolysis, cell adhesion and numerous cytoskeletal
proteins. Among the cytoskeletal proteins, we reportseveral keratin proteins as part of our “Normal Pap test
Core Proteome”. While keratins are commonly consid-
ered a contaminant in mass spectrometry, cytokeratin
intermediate filaments are components of the cornified
envelope (CE), a highly crosslinked structure formed
beneath the plasma membrane of epithelial cells that
serves a barrier function [31]. Additional structural CE
proteins, such as involucrin and periplakin, were iden-
tified in our study and in other proteomic analyses of
CVF [11,13,15,20]. Indeed, Zegels et al. [13] reported
that a “large portion” of the proteins identified in their
study were CE components, although the identification
of cytokeratins was apparently excluded from their
analysis. The presence of these and other intracellular
proteins in the cell-free residual Pap test fluid is likely
due to in situ cytolysis, through mechanical disruption,
bacterial lysis or autolysis. The cytokeratins identified
in the CVF are therefore a reflection of the cellular
composition of the female genital tract, which express
a distinctive cytokeratin profile [32].
We believe that the majority of cytoplasmic and nuclear
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Figure 3 Classification of proteins in the “Normal Pap test Core Proteome” by cellular localization and function. The 153 proteins that
comprised the “Normal Pap test Core Proteome”, as defined by their presence in 4 of the 5 individual’s Pap tests, were classified by cellular
localization and biological function using PANTHER database (version 8.1), Ingenuity IPA (version 2013, 17199142), and the UniProtKB Protein
Knowledge database. (A) The proteins were classified according to cellular localization. (B) The proteins were classified according to
biological function.
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tion of the clinical sample per se. The BD SurePathTM pre-
servative fluid contains ethanol, methanol, isopropanol,
and formaldehyde; it was developed to serve as a fixative
for cervical cells collected during a liquid-based Pap test.
The SurePathTM fixative should diminish (if not eliminate)
proteolytic degradation. Fixative solutions may crosslink
proteins and nucleic acids, so as to interfere with proteo-
lytic enzymes and potentially inhibit cellular lysis [33,34].
For our purposes of MS-based proteomics, the “fixative”
attribute of the SurePathTM preservative fluid proved to be
advantageous. Studies have shown that DNA in cervical
specimens was stable for human papillomavirus testing
when stored in SurePathTM fixative for up to 10 weeks at
ambient temperature [35]. The Material Safety Data Sheet
for the ThinPrep® PreservCyt Solution states that the cyto-
logic sample can be stored for up to six weeks at 39-99°F
[6]. Additional studies have shown that DNA could be ex-
tracted and PCR amplified from either SurePathTM or
ThinPrep® Pap test samples stored for more than 2.5 years
[36]. However, there is a paucity of information to docu-
ment the stability of proteins in these liquid-based Pap
test fixatives. Thus, the formulation of Pap test fixatives
that are currently on the market may need to be improved
upon to ensure that proteins are not degraded if they are
to be analyzed in MS-based proteomic studies.
The relative abundance of proteins in the residual Pap
test samples was estimated by NSAF, and revealed that
neutrophil gelatinase-associated lipocalin, S100A8 and
S100A9 were among the most abundant proteins identified.
All three proteins function in innate immunity, a common
function of CVF proteins [37,38], and have been previously
identified in the CVF proteome [11,13,15,20]. In one study
of CVF, a similar NSAF calculation determined that
S100A9 was the most abundant CVF protein [13]; how-
ever, although S100A9 was identified in every sample
we examined, it was among the 30 most abundant pro-
teins in only six of seven samples analyzed.
One potential advantage of using residual Pap test fluid
as a source for biomarker discovery is that CVF may not
contain the high abundance proteins that impede the
identification of low abundance proteins in similar prote-
omic analyses of serum and plasma. We examined the re-
sidual Pap test samples for the presence of serum albumin
using Western immunoblot, and found the level of albu-
min to be substantially lower than in serum. However,
when we examined the Pap test samples by mass spec-
trometry, we identified a large number of peptides specific
for albumin in the residual Pap test samples despite hav-
ing excluded samples with visible blood contamination. In
this study, we specifically chose not to deplete the highly
abundant proteins from the Pap test samples prior to MS,
since our goal was to see whether it would be feasible to
perform a limited number of steps of sample manipulationand still identify hundreds of proteins. In addition, when
we designed these studies, we were concerned that by
depleting the highly abundant proteins, we may also
deplete some of the low abundance proteins that bind
to albumin or hemoglobin.
While the presence of serum proteins is not directly
addressed in other proteomic studies of CVF, serum al-
bumin and several hemoglobin subunits were among
the 10 most abundant proteins identified in CVF by
Zegels et al. [13], and serum albumin was identified in all
ten proteomic studies of CVF compared in the Zegels et al.
review [10]. In future studies, the depletion of serum albu-
min and hemoglobin (as well as other highly abundant
serum proteins) may improve the identification of lowly
abundant CVF proteins. Furthermore, Pap test samples
from women with gynecological conditions may warrant
depletion of the highly abundant proteins in order to
identify proteins that are differentially expressed.
Importantly, our study demonstrates the feasibility of
using residual Pap test samples as a protein source for
proteomic analysis of CVF. The ability to use a com-
monly collected clinical specimen for proteomic studies
could pave the way for biomarker discovery for any
number of gynecological disorders, as well as the FDA
approved use in the screening and detection of cervical
cancer, pre-cancerous lesions, atypical cells and other
cytologic categories [4]. In addition to cytological exam-
ination of cells collected for identification of cervical
cancer, Pap test samples are now routinely used to test
for the presence of human papilloma virus DNA [39],
but could potentially be used for diagnosis of other
gynecological diseases.
The long-term goal of the research in our laboratory
has been to develop a diagnostic test for the early detection
of ovarian cancer. The median age of women who are diag-
nosed with ovarian cancer is 63 years, with almost 90% of
those diagnosed over the age of 45 [40]. In this feasibility
study, we chose to use Pap test samples from women
who were at least 50 years old, so that we could define
the “Normal Pap test Core Proteome” for this population
of women who had normal cytology reports. In ongoing
studies, we are using Pap test samples from women who
are diagnosed with ovarian cancer (all of whom are over
50 years old), with the intent of comparing their prote-
ome to this “Normal Pap test Core Proteome”. For other
gynecological conditions, it may be necessary to select a
cohort of women with a lower median age to serve as
the “normal” healthy control group.
Using an approach similar to ours, two studies exam-
ined cervical cytology specimens by MS in order to
stratify them according to cervical cancer risk [41] or for
the identification of biomarkers of cervical disease [22].
In another study, Kinde et al. [42] reported a technique
(termed Safe-SeqS assay) to detect somatic mutations in
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solution of Pap tests for the identification of gynecological
cancers. All three studies used the liquid Pap test sample;
however, they examined the cellular component of the
Pap test for either DNA mutations that were known to be
present in tumors from the same patient [42], or for MS
profiles of cytospins [41] or laser capture microdissected
cells from ThinPrep slides [22]. In our case, we used sensi-
tive MS methods to examine “cell-free” Pap test fluid to
detect proteins that are shed or secreted by cells in the fe-
male genital tract, and showed that the Pap test fluid
could be used as a source for biomarker discovery. We are
very optimistic that state-of-the-art technology for DNA
mutations [42] coupled with our MS technology for pro-
teins will one day be used routinely in the clinic for cancer
detection, including cervical neoplasms, endometrial
endometrioid and serous carcinomas, and serous tubal
intraepithelial carcinomas (“STIC”), the putative precursor
of ovarian cancers [12]. It will be necessary to more fully
explore the sources of biological, technical, and experi-
mental variations in order to define the feasibility of using
residual Pap test fixatives for clinical diagnostics.
Conclusions
We determined that the “cell-free” component of residual
Pap test fixative contains a sufficient amount of protein
for analysis by MS, and have used it to define the “Normal
Pap test Core Proteome”. Since residual Pap test fluid is
readily available from millions of patients, it represents
a valuable biospecimen source for the identification of
protein biomarkers for gynecological diseases and has
the potential to change the way that women are rou-
tinely tested for gynecological cancers.
Methods
Clinical specimens
Clinical specimens were collected per routine procedures
using the BD SurePathTM liquid-based Pap test. In the
clinic, cervical cells were collected from the ectocervix of
healthy women by a physician using a BD broom-like de-
vice specifically designed for this purpose. The detachable
head of the sampling device was immediately placed into a
BD SurePathTM vial, which contains 10 ml of a mixture
consisting of 21.7% ethanol, 1.2% methanol, 1.1% iso-
propanol, and formaldehyde [5]. In the clinical labora-
tory, the BD SurePathTM vials were shaken to remove
cells from the head of the broom-like device, and then
8 ml of the SurePathTM solution underwent automated
processing to eliminate debris and distribute a represen-
tative portion of cells on a slide in a uniform, even layer.
Cells were then stained and examined by a pathologist.
For this study, we obtained deidentified residual (waste)
Pap test samples in SurePathTM vials from the University
of Minnesota BioNet Tissue Procurement Facility withapproval from the IRB (Protocol 1101E94895). At our
institution, the SurePathTM vials are stored for one
month at room temperature after the Pap test sample
has been processed, at which time they were made
available for our use in this study. Samples selected for this
feasibility study were from women at least 50 years old
(median age of 58 years; ranging from 50–76 years) with
normal cytology and without visible blood contamination.
Sample processing
The workflow of Pap test samples from processing to
MS/MS analysis is depicted in Figure 4. SurePathTM vials
were vortexed to resuspend proteins that may have settled
during the one-month of storage at room temperature in
the cytology laboratory, as well as to release cells/proteins
from the cervical sampling device that remained in each
vial. The residual fluid was centrifuged for 5 min at 800 × g
to pellet the cells. Protein concentration in the cell-free
SurePathTM fluid was determined using the bicinchoninic
acid (BCA) protein assay in microplates (Pierce Protein
Research Products, Rockford, IL) according to the manu-
facturer’s instructions.
Polyacrylamide gel electrophoresis and Western immunoblots
Five μg of protein from the cell-free Pap test fluid of
over 100 individuals was concentrated by acetone precipi-
tation. Briefly, proteins were precipitated from the fluid
with 5 volumes of ice cold acetone overnight at −20°C,
and then centrifuged for 20 min at 6,000 × g at 4°C. The
pellet was solubilized in gel loading buffer [0.0625 M Tris,
pH 6.8; 1% SDS (w/v); 0.05% bromophenol blue (w/v); 10%
glycerol (w/v); 1% β-mercaptoethanol (v/v)]. Proteins were
separated on a 4-20% gradient Tris–HCl CriterionTM gel
(BioRad, Hercules, CA) in Tris-glycine buffer [0.1% SDS
(w/v), 25 mM Tris, 192 mM glycine, pH 8.3]. Gels were
either silver stained as previously described [43,44] or elec-
troblotted using a CriterionTM Blotter (BioRad) onto a poly-
vinylidene difluoride (PVDF) membrane (Pall Corporation,
Pensacola, FL) in transfer buffer (12.5% methanol, 25 mM
Tris base, 192 mM glycine, pH 8.0). Western immunoblots
were blocked with 5% non-fat dried milk in phosphate buff-
ered saline (PBS) with 0.05% Tween-20, and then incubated
with an affinity purified polyclonal antibody raised in rab-
bits against human serum albumin (AB-40AP, Advanced
Targeting Systems, San Diego, CA). After washing, blots
were incubated with a horseradish peroxidase conjugated
secondary antibody (Pierce), and visualized with chemilu-
minescence using SuperSignal West Femto Maximum Sen-
sitivity substrate (Pierce). Images were collected by exposure
to Kodak ×500 film (Midwest Scientific, Valley Park, MO).
Filter aided sample preparation
Equal volumes of SurePathTM fixative from 40 randomly
selected normal Pap test samples were pooled and acetone
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Figure 4 Diagrammatic representation of the workflow involved in Pap test sample preparation for MS analysis. Following a routine Pap
test, the SurePathTM vials were sent to cytopathology for a diagnosis. Excess residual SurePathTM fluid from women with normal cytology was
sent to the research laboratory. Protein concentration was determined by the BCA protein assay, proteins were precipitated with acetone, and
visualized with silver stain by SDS-PAGE. Precipitated proteins were also trypsin digested and processed by FASP, and peptides were run on HPLC
followed by MS. Data was analyzed by Sequest database searching and Scaffold analysis.
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tated proteins for pooled and individual samples were resus-
pended in 10 mM Tris, pH 7.6, 4% sodium dodecyl sulfate
(SDS). Pooled and individual samples (~50-100 ug protein)
were prepared for mass spectrometry by Filter Aided Sample
Preparation (FASP) using Nanosep Omega centrifugal de-
vices with a 10 K MW cut off (Pall Corp., Port Washington,
NY) as a reaction vessel [45,46]. Samples were reduced
by the addition of 10 mM Tris(2-carboxyethyl)phosphine
(TCEP) at room temperature. Proteins were alkylated with
50 mM iodoacetamide (Sigma-Aldrich, St. Louis, MO) and
digested with trypsin (enzyme: protein ratio 1:100) overnight
at 37°C. Peptides were desalted with C18 stage tips (Thermo
Scientific, West Palm Beach, FL) and dried under vacuum.
High pressure liquid chromatography fractionation
Trypsin digested samples were fractionated offline by high
pH reverse phase chromatography [47] using a MAGIC2002 high pressure liquid chromatography (HPLC) instru-
ment (Michrom BioResources, Inc., Auburn, CA) and C18
Gemini-NX column [150 mm × 2 mm i.d., 5 um particle,
110 Å pore size (Phenomenex, Torrence, CA)]. The flow
rate was maintained at 100 μL/min using Buffer A (10 mM
ammonium formate pH 10) and Buffer B (10% Buffer A:
90% acetonitrile) at 5-35% gradient for 60 minutes, followed
by 35-60% gradient for 5 minutes. Absorbance was moni-
tored at 215 and 280 nm wavelengths. Thirty-two fractions
were collected at 2-minute intervals and vacuum-dried.
Fractions containing peptides were resuspended in loading
solvent (98% water: 2.0% acetonitrile: 0.01% formic acid)
prior to analyzing by mass spectrometry.
Mass spectrometry and database searching
Approximately 1–1.5 ug (5 ul) aliquots of the fractions
of pooled or individual Pap test samples were run on a
LTQ Orbitrap Velos mass spectrometer (Thermo Fisher
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[48] with the exception that the higher-energy collisional
dissociation (HCD) activation energy was 0.1 ms. Sequest
(version 27, rev 12) was used for peptide matching and
protein identification. MS/MS data were searched against
a human Uniprot database (version_042012) plus com-
mon contaminants (thegpm.org/crap/index, 109 proteins),
and a concatenated reversed sequence database for a total
of 293,452 proteins. The search parameters were Fragment
Tolerance: 0.80 Da (monoisotopic), Parent Tolerance:
0.073 Da (monoisotopic), carbamidomethyl as the fixed
modification, methionine oxidation as the variable modifi-
cation, trypsin digestion, two missed cleavages allowed, and
95% confidence for the detected protein threshold.
The dta/out files generated by Bioworks were analyzed in
Scaffold (version _3.6.2, Proteome Software Inc., Portland,
OR) to validate MS/MS based peptide and protein iden-
tifications and for relative protein quantitation. Peptide
identifications were accepted if they could be estab-
lished at >95.0% probability as specified by the Peptide
Prophet algorithm [49]. Protein identifications were ac-
cepted if they could be established at >99.0% probability
by the Protein Prophet algorithm [50], and contained at
least 2 identified peptides. Rates of false positive identi-
fications were estimated using the target-decoy method
[51]. False positive rates were < 1.0% for all experiments.
Calculations of the relative abundance of proteins
For semi-quantitative estimation of the abundance of
proteins, we determined the total count of MS/MS spec-
tra for each protein. To correct the spectral count for
differences in protein size, we normalized by dividing
the number of counted spectra to the length of proteins
(number of observable peptides) in in-silico trypsin di-
gestion [13,27,28]. We then calculated the Normalized







Where S is the number of spectral counts for protein
k, L is the length of protein k and N is the total number
of proteins identified. We multiplied by 1000 for con-
venience in presentation of small numbers.
Classification of proteins by cellular localization and
biological function
The proteins identified by MS were classified by cellular
localization and biological function using PANTHER
database (version 8.1) [24] and Ingenuity IPA (version 2013,
17199142, Ingenuity® Systems, www.ingenuity.com) and the
UniProtKB Protein Knowledge database.Additional files
Additional file 1: MS/MS data of pooled Pap test samples.
Additional file 2: MS/MS data of Pap test fluid from 5 individuals.
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